Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jul 02, 2022 7:08am
217 Views
Post# 34797187

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Updated clinical trial

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Updated clinical trial

Yep. I pointed out to our new IR that uncertainty has caused a one way market where a $40,000 trade can push the stock price down by 10%, as happened in 3 hours yesterday.  They try to build the demand side, but it's not worth the effort unless they can seriously dent the uncertainty that's hung over them for 2 years now.


Anything they can do to put meat on the bone for their strategy would help.  Vague assertions are fine when you only know vague facts on a trial, but by now, after a year, they must have learned some facts on human interaction. Everyone knows there will be positives and negatives.  No trial is without them.  These things can be understood and discussed.  I just hope the upcoming releases provide depth and context.  Of course, I hope the positives outweigh the negatives by a good amount and we can see the target is valid, off-target is understood and there is a way to counter it, and that the age-old drug taxol is doing in their tumors what it's done in millions of tumors over the last 30 years.  Plus, some good signs on bypassing resistance, nailing stem cells, stopping metastices and vascular mimicry being heavily disrupted.  Give us the meat, not the vague crumbs.


SPCEO1 wrote: Like Luke attacking the death star in the first Star Wars movie, you need to "stay on target", especially since TH is now so close to the target. Don't get distracted by someone else panicking and selling a small amount of shares in a hurry.

PWIB123 wrote: I feel like I've been knocked down by an upper cut and am relentlessly getting kicked in the head over and over again.  I can withstand a few more blows, but it's getting hard to see through the blood.  I might need the medics to bring in the stretcher soon.  I just hope I don't have to stay in recovery for long.




<< Previous
Bullboard Posts
Next >>